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Abstract
Background: Syndecan-1 plays a vital role in the suppression, transformation, and migration of several cancer
types, including colorectal cancer (CRC). However, the prognostic and clinical significance of syndecan-1 in CRC
remains conflicting. Therefore, we performed a meta-analysis to clarify this relationship.
Methods: A comprehensive literature search for relevant studies published up to December 2014 was performed
using PubMed, EMBASE, and Ovid library database. The odds ratio (OR) and pooled hazard ratio (HR) with their
95 % confidence intervals (CI) were used to estimate the effects.
Results: Ten studies with 888 CRC patients were selected for evaluation. The results showed that syndecan-1
expression was lower in CRC tissue than in normal colorectal tissue (OR = 0.02, 95 % CI = 0.00–0.09), and lower in
the advanced stage than in the early stage (OR = 2.24, 95 % CI = 1.14 − 4.42). Additionally, syndecan-1 expression
was higher in well and moderately differentiated CRC than in poorly differentiated CRC (OR = 2.91, 95 % CI = 1.21–
6.98); no significant difference was found in patients with or without lymph node metastasis (OR = 0.91, 95 % CI =
0.34–2.43) and distant metastasis (OR = 0.89, 95 % CI = 0.19-4.21). The pooled results showed that syndecan-1
expression was not associated with survival in CRC patients (HR = 0.93, 95 % CI = 0.86–1.01).
Conclusion: This meta-analysis indicated that loss of syndecan-1 expression is associated with CRC development,
histological differentiation, and clinical stage, but not with lymph node metastasis and distant metastasis. In addition,
these findings fail to support the prognostic significance of syndecan-1 in CRC.
Background
Colorectal cancer (CRC) is one of the most common
gastrointestinal cancers. CRC patients with metastatic
disease often have a poor prognosis [1]. Surgical resec-
tion is the main approach for the treatment of CRC but
has limited effectiveness in patients with locally invasive
or metastatic disease. Therefore, understanding the mech-
anisms of disease progression and identification of prog-
nostic markers are essential in improving the treatment of
CRC. Syndecan-1 (CD138), a transmembrane proteogly-
can, plays a critical role in cell-cell and cell-extracellular
matrix adhesion and acts as a growth factor coreceptor
[2]. Syndecan-1 is highly expressed in normal epithelial
cells, and loss of expression is associated with epithelial-
mesenchymal transition and the transformed phenotype
[3, 4]. Furthermore, many studies have shown that loss of
syndecan-1 expression is associated with tumor develop-
ment and progression [5–7].
Syndecan-1 has been reported to have prognostic
value in many types of cancers such as hepatocellular
cancer [8], laryngeal cancer [9], gastric cancer [10], and
lung cancer [11]. Studies investigating the association of
syndecan-1 expression with clinical parameters and
prognosis in CRC patients have yielded inconsistent re-
sults. Fujiya et al. [12] found that CRC patients with
syndecan-1 negative tumors had a high incidence of
lymph node and liver metastasis. Furthermore, the sur-
vival rate in patients with syndecan-1 negative tumors
decreased significantly in a stage-independent manner.
Consistent with this, Wang et al. [13] showed that high* Correspondence: chenls3001@163.com
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preoperative syndecan-1 serum level was significantly
associated with poor disease-free survival. However,
Lundin et al. [14] showed that the cumulative 5-year
survival was not significantly different between pa-
tients with strong and weak syndecan-1 expression.
Hashimoto et al. [15] and Mitselou et al. [16] also
failed to demonstrate the prognostic significance of
syndecan-1 expression in CRC. Differences in sample
size (i.e., statistical power) or other study parameters
may have contributed to these discrepant findings.
Meta-analysis is a quantitative method for combining
data from multiple studies in a single study and pro-
vides more reliable results compared with individual
studies. Therefore, we performed a meta-analysis to exam-
ine the relationship between syndecan-1 expression and
clinical parameters and prognosis in CRC patients.
Materials and methods
Search strategy and selection criteria
The meta-analysis was performed in accordance with
the guidelines of the Preferred Reporting Items for
Systematic Review and Meta-analyses statement [17].
We systematically searched PubMed, EMBASE, Ovid
library database, Chinese National Knowledge Infra-
structure, Chinese Biomedical Database, and conference
abstracts from recent presentations at international meet-
ings, such as ASCO and ESMO, to identify suitable
studies prior to December 2014. The Medical Subject
Headings and text words used for the search were
“colorectal neoplasms” or “colorectal cancer,” “synde-
can” or “CD138,” and “prognosis.” The differences in
truncation symbols and wildcards between databases
were used for the retrieval strategy in order to identify
potentially relevant studies. The searches were limited
to human studies. Articles were also identified using
the related articles function in PubMed. References
within the identified articles were also searched manu-
ally. Potentially relevant articles were screened by two
independent reviewers. Disagreements between the re-
viewers were resolved by discussion or upon consensus
from a third reviewer. The study protocol was approved
by the ethics committee of the First Affiliated Hospital
of Guangxi Medical University.
Inclusion and exclusion criteria
The inclusion criteria were as follows: 1) patients with
confirmed diagnosis of CRC; 2) assessment of the associ-
ation of syndecan-1 expression with clinical parameters
and prognosis in CRC; and 3) detection of syndecan-1
expression in CRC tissue by immunohistochemistry
(IHC). Exclusion criteria were as follows: 1) review arti-
cles, case reports, and animal studies; 2) cell line and hu-
man xenograft studies; 3) studies using methods other
than IHC for detection of syndecan-1 expression; and 4)
low-quality studies, including studies without data on
patients’ demographic characteristics or IHC findings.
When the same patient population was reported in
several publications, only the most complete study was
included in the analysis. Two reviewers independently
assessed study eligibility. Disagreements between re-
viewers were resolved by consensus.
Data extraction and quality assessment
Study data were assessed and extracted independently by
two reviewers. Disagreements between the reviewers
were resolved by discussion and consensus. Extracted
data included author names, year of publication, sample
source, number of male and female patients, tumor clas-
sification system, IHC methodology (antibody source, di-
lution), and clinical parameters (tumor stage, lymph node
metastasis, distant metastasis). In the present study, in
order to reduce the bias, we combined both the Dukes
and TNM staging systems in the AJCC staging system
(seventh edition, 2010) and reassessed the association be-
tween syndecan-1 expression and CRC.
The methodological quality of each study was assessed
and scored according to the Newcastle-Ottawa Quality
Assessment Scale [18]. The following items were assessed
in each study: exposed cohort, ascertainment of exposure,
outcome of interest, comparability of cohorts, assessment
of outcome, and adequacy of follow-up. Studies with a
score of 6 or higher were considered to be of high quality.
Two reviewers independently assessed study quality.
Quality scores were obtained by consensus.
Statistical analysis
The pooled odds ratio (OR) with 95 % confidence inter-
val (CI) was used to quantitatively determine the asso-
ciation between syndecan-1 expression and clinical
parameters in CRC patients, whereas the hazard ratio
(HR) with 95 % CI was used to quantitatively evaluate
the association between syndecan-1 expression and pa-
tient survival. Heterogeneity among studies was evalu-
ated using Cochran’s Q test and the I2 statistic. The
pooled OR and HR were calculated using a fixed-effects
model (Mantel-Haenszel method) in the absence of
substantial study heterogeneity (I2 < 50 %). Otherwise, a
random-effects model (DerSimonian-Laird method)
was used. Sensitivity analysis was performed by remov-
ing studies on chemotherapy and removing each study
in turn to test the reliability of the overall pooled re-
sults. Publication bias was assessed using Egger and
Begger's tests. All statistical analyses were performed
using Stata 11.2 software (Stata Corp, College Station,
TX). A two-tailed P value <0.05 was considered statisti-
cally significant.
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Results
Identification of relevant studies
The initial literature search retrieved 47 potentially eli-
gible studies based on the predefined selection criteria.
After a detailed evaluation, 37 studies were excluded, in-
cluding 12 laboratory studies, 8 reviews, 8 studies with
insufficient data, and 9 irrelevant studies. Thus, 10 stud-
ies [12–15, 19–24] involving 888 patients were included
in the meta-analysis (Fig. 1).
Study characteristics and quality assessment
All included studies used IHC to detect syndecan-1 ex-
pression. Four studies [12, 14, 15, 21] provided follow-
up data. Four [12, 13, 15, 19] and 6 [14, 20–24] studies
used the TNM and Dukes classifications for tumor sta-
ging, respectively. The quality of the studies was high,
with scores ranging from 7 to 9. Patient demographic
data from each of the included studies are shown in
Tables 1 and 2.
Syndecan-1 expression in CRC tissue
In our study, we classified syndecan-1 expression into
two types according to the IHC results: negative/low
syndecan-1 expression or positive/high syndecan-1 ex-
pression. Three studies involving 194 samples assessed
syndecan-1 expression in CRC and normal colorectal tis-
sues. Significant heterogeneity across the studies was not
observed (I2 = 38.8 %, P = 0.195; Fig. 2a). Syndecan-1 ex-
pression was lower in CRC tissues compared with nor-
mal colorectal tissues (fixed-effects model: OR = 0.02,
95 % CI = 0.00 − 0.09).
Association of syndecan-1 expression with clinical
parameters in CRC
The association of syndecan-1 with clinical parameters
is shown in Figs. 2b-e. Syndecan-1 expression was higher
in well and moderately differentiated CRCs compared
with poorly differentiated CRCs (random-effects model:
OR = 2.91, 95 % CI = 1.21 − 6.98). However, significant
heterogeneity across the studies was observed (I2 =
Fig. 1 Flowchart of study selection
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72.4 %, P = 0.001). After combining both the Dukes and
TNM staging systems in the AJCC staging system, we
found that syndecan-1 expression was significantly lower
in advanced-stage (T3-4 stage) than in early-stage (T1-
2 stage) CRC (random-effects model: OR = 2.24, 95 %
CI = 1.14 − 4.42; I2 = 63.7 %, P = 0.005). Syndecan-1 ex-
pression was not significantly different between patients
with and without lymph node metastasis (random-ef-
fects model: OR = 0.91, 95 % CI = 0.34 − 2.43) or distant
metastasis (random-effects model: OR = 0.89, 95 % CI =
0.19 − 4.21). However, significant heterogeneity across the
studies was observed (lymph node metastasis: I2 = 72.4 %,
P = 0.001; distant metastasis: I2 = 84.3 %, P < 0.000).
Association of syndecan-1 expression with prognosis in
CRC
Four studies provided data regarding the association of
syndecan-1 expression with overall survival of CRC pa-
tients. However, we excluded one study (Wang et al. [13])
that provided data on disease-specific survival time
from the pooled analysis. Heterogeneity among the four
studies was significant (I2 = 73.9 %, P = 0.009). The
Table 1 Characteristic of selected studies in the meta-analysis






Wang et al 2014/China 25/27 TNM Maixin NA 40 mo 8
Yang et al 2010/China 33/25 Duke Santa Cruz 1:50 5 yrs 8
Pap et al 2009/Romania 71/46 Duke Fremont 1:50 NA 8
Hashimoto et al 2008/USA 79/52 TNM Serotec 1: 100 38 mo 9
Qi et al 2008/China 33/19 Duke Maixin NA NA 7
Feng et al 2007/China 20/11 TNM Zhongshan 1:75 NA 8
Lundin et al 2005/Finland 118/119 Duke Serotec 1:100 116 mo 9
Zhou et al 2005/China 33/19 Duke Zhongshan NA NA 7
Zuo et al 2004/China 29/22 Duke Zhongshan NA NA 7
Fujiya et al 2001/Japan 65/40 TNM Santa Cruz 1:50 10 yrs 9
Table 2 Characteristic of selected studies in the meta-analysis
Author Clinical parameters
assessment (number)
Scoring system (Positivity cells) Number of patients Epitope retrieval method
Wang et al T, L, H, D, F. (52) histoscore = area × intensitya High level (26), Low level (26) NA
Yang et al F. (58) histoscore = area × intensitya Positive (19), Negative (39) HIER
Pap et al T, L, H, D. (117) Frequency of cells + intensityb G0 (2), G1-3 (115) pressurized steam
cooking
Hashimoto et al T, L, H, D, F. (131) 0 (< 5 %); 1+ (5 % – 25 %); 2+ (25 % – 75 %),
3+ (> 75 %)
0 (38), 1+(27), 2+(49), 3+(17) antigen retrieval
solution
Qi et al T, L, H, D, E. (52) 0 (< 5 %); 1+ (5 % – 25 %); 2+ (25 % – 75 %),
3+ (> 75 %)
Positive (34), Negative (18) HIER
Feng et al T, L, H, D, E. (31) 0 (< 5 %); 1+ (5 % – 25 %); 2+ (25 % – 75 %),
3+ (> 75 %)
Positive (25), Negative (6) HIER
Lundin et al T, H, F. (237) Weak: < 30 %, Strong: > 30 % Weak (86), Strong (151) NA
Zhou et al T, L, H. (52) 0 (< 5 %); 1+ (5 % – 25 %); 2+ (25 % – 75 %),
3+ (> 75 %)
0 (18), 1+(13), 2+(14), 3+(7) HIER
Zuo et al T, L, H, D, E. (51) 0 (< 5 %); 1+ (5 % – 50 %); 2+ (> 50 %) 0 (31), 1+(17), 2+ (3) HIER
Fujiya et al T, L, F. (105) – (< 5 %); + (5 % – 25 %); ++ (25 % – 75 %), +++
(> 75 %)
– & ± (36), + & ++ (69) HIER
NA not available, T depth of infiltration, L lymph node metastasis, D distant metastasis, H Histological grade, F follow-up, E expression of tumor, HIER heat induced
epitope retrieval
aThe intensity of membranous staining was graded as negative (-), weak (+), moderate (++) and intense (+++). The percentage of cells was graded as follows:
0 (<5 %), 1 (5–25 %), 2 (26–50 %), 3 (51–75 %) and 4 (> 75 %). Imunohistochemical score (histoscore) = values of the intensity × the percentage of cells (area).
bFrequency (F) of immunopositive tumor cells: F0: 0–5 %, F1: 6–30 %, F2: 31–75 %, F3: 76– 100 %; and the signal intensity (I): absent (0), weak (1), moderate (2),
strong (3). Immunohistochemical grading (IG) system: IG0 (absent): F+I= 0–1; IG1 (weak): F+I=2–3; IG2 (moderate): F+I= 4; IG3 (strong): F+I= 5–6
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pooled results showed that syndecan-1 expression was
not associated with prognosis in CRC patients (ran-
dom-effects model: HR = 0.93, 95 % CI = 0.86 − 1.01;
Fig. 2f ).
Sensitivity analysis and publication bias
The patients in the study by Wang et al. [13] study re-
ceived chemotherapy, hence to eliminate the effect of
chemotherapy and test the robustness of the overall
results, we excluded data of Wang et al.’s study from the
sensitivity analysis and found that the results were in
line with the overall results (data not shown).
We also performed sensitivity analysis by removing each
study in turn from the analysis. The pooled ORs and HRs
were not significantly changed, indicating the stability of
our analyses. The funnel plots were largely symmetrical,
and the results of the Egger and Begger's tests showed no
evidence of significant publication bias. See Fig.3.
Fig. 2 Meta-analysis of syndecan-1 expression in CRC. a CRC and normal colorectal tissue; b histological differentiation grade; c clinical stag; d
lymphoid node metastasis; e distant metastasis; f survival time. OR: odds ratio; HR: hazard ratio. The pooled OR and HR were calculated using a
random-effects model
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Discussion and conclusion
Syndecan-1 is a member of a four-member family of
cell surface heparan sulfate proteoglycans. Syndecan-1
is known to play important roles in the regulation of
epithelial homeostasis, proliferation, and migration [25].
Syndecan-1 has also been shown to suppress transform-
ation and migration in several cancer cell lines. Syndecan-
1 expression is often lost in a wide range of cancer cell
lines and cancer tissues. Several mechanisms have been
suggested to explain the relationship between loss of epi-
thelial syndecan-1 expression and cancer progression.
Cancer development and progression is accompanied
by the disruption of cell-cell and cell-matrix adhesion
[26]. As an adhesion molecule, syndecan-1 influences
the tumorigenic activity of cancer cells by altering
extracellular matrix adhesion and cell morphology [27].
Disruption of cell-cell and cell-extracellular matrix ad-
hesion by epithelial syndecan-1 loss leads to cancer cell
growth, migration, and dissemination and thus, to poor
patient prognosis [28, 29].
In the present meta-analysis, we found that syndecan-1
expression is lower in CRC tissues compared with normal
Fig. 3 Funnel plots suggesting there were no publication biases in the meta-analysis. a CRC and normal colorectal tissue; b histological differentiation
grade; c clinical stag; d lymphoid node metastasis; e distant metastasis; f survival time
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colorectal tissues. This finding indicates that loss of
syndecan-1 expression in colonic epithelial cells is associ-
ated with CRC development. The pooled data also showed
that syndecan-1 expression is higher in well and moder-
ately differentiated CRCs compared with poorly differenti-
ated CRCs. Thus, syndecan-1 expression was associated
with histological grade in CRC. In addition, the pooled
results suggested that syndecan-1 expression is lower in
the advanced stage than in the early stage. However, our
analysis failed to demonstrate an association of syndecan-
1 expression with lymph node metastasis. This finding is
inconsistent with that reported by Pap et al. [24], but
agreed with that reported by Fujiya et al. [12]. The reasons
for these contradictory findings are not known. Thus,
further investigation is necessary to clarify this association.
The association of syndecan-1 with clinical character-
istics differs according to cancer type. Syndecan-1 has
been associated with a high incidence of metastasis in
patients with poorly differentiated hepatocellular carcin-
oma [8]. However, syndecan-1 expression was not differ-
ent between early and advanced-stage pancreatic cancer
[30]. Although reduced syndecan-1 mRNA expression
conferred a growth advantage to cervical carcinoma cells
[31], syndecan-1 expression was not associated with clin-
ical stage or outcome in cervical carcinoma patients [32].
Currently, the AJCC seventh edition TNM classification
has become the principal method for prognosis assess-
ment in CRC. In our study, after combining both the
Dukes and TNM staging systems in the AJCC TNM sta-
ging system and reassessing the association, we found an
association of syndecan-1 expression with clinical stage,
suggesting that syndecan-1 expression reduced in the ad-
vanced stage of CRC. Regarding the prognostic value of
syndecan-1, our analysis failed to show an association be-
tween loss of syndecan-1 expression and survival time in
CRC patients. However, although the four studies in-
cluded had 531 patients, which seems to provide sufficient
statistical power, the pooled HR is approximately 1 for
three out of the four investigated studies, and there was
significant heterogeneity across the studies, indicating that
the prognostic value will be limited and further study fo-
cusing on this parameter is needed.
Our meta-analysis is the first to clarify the relationship
between syndecan-1 expression and clinical parameters
and prognosis in CRC. Our meta-analysis was able to
overcome the small sample size of individual studies,
thereby enhancing statistical power and providing a more
reliable estimation of these associations. In addition, the
results indicated the absence of significant publication
bias, suggesting the robustness of the results. To date,
IHC is the most common method used to detect the ex-
pression of cytokines at the protein level, while other
methods, such as PCR, that detect expression at the gene
level have also been used widely. These methods are
mutually complementary. In our study, we chose IHC be-
cause most studies used this method to detect the expres-
sion of syndecan-1, and hence we could obtain a large
sample size, which would lead to more reliable pooled re-
sults. However, further meta-analysis using other methods
is warranted to confirm our results.
Our study has several limitations and thus, the results
should be interpreted cautiously. First, significant
study heterogeneity was present for several parameters,
which decreased the robustness of the conclusions.
Random-effect models and sensitivity analysis were
used to reduce the impact of study heterogeneity on
the meta-analysis results. Second, although 10 studies
were included in the analysis, the number of patients
was relatively small. A larger sample size is needed to
obtain more reliable results. Third, the possibility of
information and selection biases and unidentified con-
founders could not be completely excluded, as all in-
cluded studies were observational. Fourth, although we
searched several databases, other databases, such as
Oncomine database, were not searched. Therefore,
some relevant studies may have been missed, which
may have undermined the robustness of the results.
Fifth, CRC incidence greatly differs between Asian and
Caucasian countries, but most patients included in our
study were of Asian ethnicity, which may cause some
selection bias. Finally, not much consensus exists on
the evaluation of immunohistochemistry data. Thus,
the pooled data in present study are subject to the bias
caused by the various scoring systems used. Therefore,
our results should be interpreted with caution.
In conclusion, the results of our study demonstrate that
loss of syndecan-1 expression correlates with histological
grade and tumor stage, but not with lymph node metastasis
or distant metastasis, in CRC. Furthermore, syndecan-1
expression does not have prognostic value in CRC patients.
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